Differences in immune tumor microenvironment between primary and metastatic castration-resistant prostate cancer.
Explore this paper's citation graph
Summary
The data indicate the development of tumor-favoring iTME in the course of progression to mCRPC while on ADT, characterized by increased M2 macrophage infiltration that may provide a novel and important therapeutic target.
- Type
- article
- Published
- 2019-03-10
- Cited by
- 0
- References
- 0
- OpenAlex
- https://openalex.org/W2957506312
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:199046768
Keywords
Prostate cancer, Enzalutamide, Medicine, Tumor microenvironment, CD8
References
No references recorded for this paper.
Cited by
No citing papers recorded for this paper.
Related papers
- A drug safety evaluation of enzalutamide to treat advanced prostate cancer
- Cancer-associated PTEN mutants act in a dominant negative manner to suppress PTEN protein function
- Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer
- The expression significance and associativity of ILK and PTEN in gastric cancer tissue
- Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial.
- Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer
- Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)
- 위암에서 PTEN 발현 및 신생혈관 형성의 관련성
- Data from Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer